Sanofi Consumer Healthcare India Past Earnings Performance
Past criteria checks 1/6
There is insufficient data on Sanofi Consumer Healthcare India's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | n/a |
| Return on equity | 21.3% |
| Net Margin | 17.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sanofi Consumer Healthcare India makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,314 | 393 | 406 | 0 |
Quality Earnings: SANOFICONR has a large one-off loss of ₹255.0M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: Insufficient data to determine if SANOFICONR's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if SANOFICONR's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare SANOFICONR's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: Insufficient data to determine if SANOFICONR's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: SANOFICONR's Return on Equity (21.3%) is considered high.